default author photo

Nuria Lainez

affiliation not provided to SSRN

SCHOLARLY PAPERS

1

DOWNLOADS

27

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Adverse Events in the Placebo Arm of Solo2/Engot-Ov21 Maintenance Trial of Olaparib in Recurrent Ovarian Cancer

Number of pages: 27 Posted: 24 Sep 2024 Last Revised: 01 May 2025
The University of Sydney, The University of Sydney, The University of Sydney - NHMRC Clinical Trials Centre, Université de Caen, University College London - UCL Cancer Institute, Harvard University - Harvard Medical School, University of Toronto - University Health Network, Tel Aviv University, affiliation not provided to SSRN, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Saitama Medical University International Medical Center (SIMC), affiliation not provided to SSRN, affiliation not provided to SSRN, ARCAGY-GINECO and The University of Sydney
Downloads 27 (1,359,097)

Abstract:

Loading...

Placebo, adverse events, trial design, ovarian cancer, maintenance therapy, PARPi